The articles listed on this page are from a variety of sources. 
1. The staff of DBS-STN often attends conferences or educational opportunities both nationally and internationally, and a brief understandable write-up of the information presented at the event will be provided for our readers to review. 
2. DBS-STN staff also identifies or writes various articles related to topics that are thought to be of interest for the reader of www.DBS-STN.org. 

Browse by Topic:
Search:

NeuroDerm Initiates Patient Enrollment in a Phase III Trial of ND0612L for the Treatment of PD


(August 25, 2016) – NeuroDerm, a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, announced that it has initiated enrollment of Parkinson's disease patients in a Phase III efficacy trial (trial 007, named the "iNDiGO" trial) of ND0612L, the company’s low-dose continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid formulation. Read more…



Article Archive

back